Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
Tarsus Pharmaceuticals plans to present 11 scientific abstracts at the American Academy of Optometry 2026 Annual Meeting, Sept. 30-Oct. 3 in Anaheim, California. The abstracts cover Demodex blepharitis burden and diagnosis, real-world outcomes with XDEMVY, and ocular rosacea prevalence, reinforcing the commercial franchise and the TP-04 pipeline.
Key figures
- Abstracts count
- 11
- Db patients potential
- 25 million Americans
- Ocular rosacea patients
- 15-18 million people in the United States
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.